A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

Exclusion Criteria52

• Medical conditions
• Any primary kidney disease with a high incidence of recurrent primary kidney disease within the allograft
• Evidence of recurrent primary kidney disease within the current allograft
• Previous allograft loss secondary to recurrent primary kidney disease
• History of more than one organ transplanted (that is, kidney-liver, simultaneous double kidney or kidney-other organ(s) transplanted).
• Subjects with an episode of acute allograft rejection over the six months (180 days) prior to enrolment
• Panel Reactive Antibodies (PRA) calculated PRA (cPRA) or Calculated Reaction Frequency (cRF) score that is unknown at the time of transplant
• VZV serostatus unknown prior to transplant
• Subjects with advanced chronic kidney disease
• Evidence of significant proteinuria (≥ 200 g/mol creatinine) believed to be of renal origin (an example of non-renal origin is proteinuria from mucus in a reconstructed bladder)
• Subjects without multiple dialysis options in the event acute or chronic dialysis needed.
• History of unstable or progressive neurological disorder.
• Subjects ≤ 5 years of age with a history of one or more simple or complex febrile seizures
• Subjects \> 5 years with history of one or more complex febrile seizures
• Occurrence of a varicella or HZ episode by clinical history within the 6 months (180 days) preceding Visit Day 1
• Any autoimmune disease, with the following exceptions which do not constitute an exclusion criterion:
• IgA nephropathy
• Rapidly progressive glomerulonephritis
• Membranous glomerulonephritis
• Idiopathic Type I membranoproliferative glomerulonephritis
• Diabetes mellitus (type 1 and 2) with diabetic nephropathy
• Confirmed or suspected Human Immunodeficiency Virus or primary immunodeficiency disease
• Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
• Any condition which, in the judgement of the investigator would make intramuscular injection unsafe.
• Atypical Haemolytic Uraemic Syndrome.
• Prior/Concomitant therapy
• Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before Visit Day 1 (Day -29 to Day -1), or planned use during the study period.
• Subject in receipt of treatment for rejection during the six months (180 days) prior to enrolment.
• Use of anti-CD20 or other B-cell monoclonal antibody agents within 1 year of Visit Day 1 or planned administration during the duration of the study.
• Administration of blood products 3 months (90 days) prior to Visit Day 1 or planned administration during the duration of the study.
• Administration of immunoglobulins 6 months (180 days) prior to Visit Day 1 or planned administration of immunoglobulins during the duration of the study.
• Administration or planned administration of a vaccine within 30 days prior to Visit Day 1 up to Visit Month 2 with the exception of an inactivated or subunit influenza vaccine which may be given 8 days prior to or 14 days after Visit Day 1 and 8 days prior to or 14 days after Visit Month 1.
• Previous vaccination against HZ
• Varicella vaccination within the 6 months (180 days) preceding Visit Day 1
• Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine
• Prior/Concurrent clinical study experience
• • Concurrent or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
• available locally through compassionate use programs,
• submitted for and pending local/country registration,
• approved and registered for use in other countries with well-documented Summary of Product Characteristics or Prescribing Information
• The name of the active component(s) of these immunosuppressants must be provided in the concomitant medication listing
• Other exclusions
• Child in care
• Pregnant or lactating female
• Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) between one month (30 days) prior to Visit Day 1 through two months (60 days) after Visit Month 1.
• Evidence or high suspicion, in the opinion of the investigator, of non-compliance or non-adherence to use of induction and/or maintenance immunosuppressive therapies.
• Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit
• Completion must cover the 7 days immediately prior to randomisation (Visit Day 1).
• Completion is defined as a minimum of 6 days completed.
• Subjects with less than 6 days completed may be offered a new date for Visit Day 1 and the opportunity to comply with the completion of the 7-day pre-vaccination diary card prior to the new planned Visit Day 1.
• Any study personnel or their immediate dependants, family, or household member.